Genetic polymorphism in ATG16L1 gene influences the response to adalimumab in Crohn's disease patients-Reference-Cited by-同舟云学术

Genetic polymorphism in ATG16L1 gene influences the response to adalimumab in Crohn's disease patients

Published:2015-03 Issue:3 Volume:16 Page:191-204
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Koder Silvo¹,Repnik Katja²³,Ferkolj Ivan⁴,Pernat Cvetka¹,Skok Pavel¹²,Weersma Rinse K⁵,Potočnik Uroš²³

Affiliation:

1. University Medical Centre Maribor, Ljubljanska 5, Maribor, Slovenia

2. Center for Human Molecular Genetics & Pharmacogenomics, Faculty of Medicine, University of Maribor, Taborska 8, Maribor, Slovenia

3. Faculty for Chemistry & Chemical Engineering, University of Maribor, Smetanova 17, Maribor, Slovenia

4. Department of Gastroenterology, Division of Internal Medicine, University Medical Centre Ljubljana, Japljeva 2, Ljubljana, Slovenia

5. Department of Gastroenterology & Hepatology, University of Groningen & University Medical Center Groningen, Groningen, The Netherlands

Abstract

Aim: To see if SNPs could help predict response to biological therapy using adalimumab (ADA) in Crohn's disease (CD). Materials & methods: IBDQ index and CRP levels were used to monitor therapy response. We genotyped 31 CD-associated genes in 102 Slovenian CD patients. Results: The strongest association for treatment response defined as decrease in CRP levels was found for ATG16L1 SNP rs10210302. Additional SNPs in 7 out of 31 tested CD-associated genes (PTGER4, CASP9, IL27, C11orf30, CCNY, IL13, NR1I2) showed suggestive association with ADA response. Conclusion: Our results suggest ADA response in CD patients is genetically predisposed by SNPs in CD risk genes and suggest ATG16L1 as most promising candidate gene for drug response in ADA treatment. Original submitted 24 September 2014; Revision submitted 1 December 2014

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs.14.172

Reference66 articles.

1. Extraintestinal manifestations of inflammatory bowel disease: Epidemiology, diagnosis, and management

2. Inflammatory Bowel Disease

3. Efficacy of adalimumab for the management of Inflammatory Bowel Disease in the Clinical Setting

4. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial

5. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision medicine in inflammatory bowel disease;Precision Clinical Medicine;2023-10-25

2. Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review;World Journal of Gastroenterology;2023-08-07

3. Apoptosis and inflammatory genes variants in primary non-response to anti-TNF therapy in Crohn’s disease patients;European Journal of Gastroenterology & Hepatology;2023-07-31

4. Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies;Nature Reviews Rheumatology;2023-06-29

5. Harnessing the Power of Precision Medicine and Novel Biomarkers to Treat Crohn’s Disease;Journal of Clinical Medicine;2023-04-04